CUR - Neuralstem Inc.
Company Overview
US District Court Rules In Favor Of Neuralstem In Patent Infringement Case
US District Court Rules In Favor Of Neuralstem In Patent Infringement Case
The District Court held a bench trial on the issue of standing in December of 2014. In its 29-page Memorandum Opinion, the U.S. District Court for the District of Maryland ruled that a third-party scientist is a co-owner and co-inventor of the patents-in-suit. As a result, StemCells, Inc. lacked standing on its own to bring its patent infringement claims against Neuralstem, Inc. and the case was dismissed with prejudice.
Read Full Article http://finance.yahoo.com/news/us-district-court-rules-favor-114500810.html
Website: http://www.neuralstem.com/
Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds. The company's stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of all types.
Its clinical program products include NSI-566, which is in ongoing Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as in Phase I clinical trial for chronic spinal cord injury. The company's clinical development products also comprise NSI566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; NSI189 that completed Phase Ia and Ib trials for the treatment of major depressive disorders; and NSI189, which is in Phase Ib preparation for cognitive deficit in schizophrenia. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Why we like CUR:
Positive Patent News Today
•
Closed Near High OF Day Today
•
Strong Trading Volume Into The Close
•
Stock Was Trading Above $3.50 In March
•
MLV & Co. Gave CUR A 'Buy' Rating With A Target Of $6 In April
•
Napodano From Zacks Posted Today That He Is Long On CUR
•
CUR Neuralstem Have Treatments For 14 Major Ailments In Their Pipeline
Cell Therapy Treatments in Development
http://www.neuralstem.com/patient-info-treatments-in-development
ALS
FDA-approved multi-center dose-escalation Phase II NSI-566/ALS clinical trial primarily evaluating safety concluded in 1Q15. NSI-566/ALS controlled Phase II expected to commence in 2015. More
Spinal Cord Injury
FDA-approved Phase I safety trial transplanting NSI-566 into the T2-T12 lumbar regions of four chronic SCI patients commenced surgeries in September 2014 at University of California, San Diego. Acute SCI Phase I/II trial in Seoul, South Korea, awaiting IND approval. More
Ischemic Stroke
NSI-566 Phase I / II trial for ischemic stroke commenced in December 2013, in collaboration with BaYi Brain Hospital in Beijing. Phase II commencement expected in 2015. More
Multiple Sclerosis
Preclinical phase with NSI-566. Further clinical development on multiple sclerosis application pending NSI-566 ALS ongoing trial.
Optic Neuritis
Preclinical phase with NSI-566. Further clinical development on optic neuritis application pending NSI-566 ALS ongoing trial.
Alzheimer’s Disease
Preclinical phase with HK532-IGF-1, human cortex-derived neural stem cells that have been engineered to secrete human insulin-like growth factor 1 (IGF-1). In animal data presented at the Congress of Neurological Surgeons 2014 Annual Meeting, the cells rescued spatial learning and memory deficits in an animal model of Alzheimer’s disease. Additional animal data presented at the International Society for Stem Cell Research 2015 Annual Meeting showed a beta-amyloid plaque reduction in both the cortex and hippocampus; amyloid plaque is one of the two hallmarks of AD.
Traumatic Brain Injury
Preclinical phase with NSI-566. Further clinical development on traumatic brain injury application pending NSI-566 ALS ongoing trial.
Peripheral Nerve Injury
Preclinical phase with NSI-566. Further clinical development on peripheral nerve injury application pending NSI-566 ALS ongoing trial.
Diabetic Neuropathy
Preclinical phase with NSI-566. Further clinical development on diabetic neuropathy application pending NSI-566 ALS ongoing trial.
Lysosomal Diseases
Preclinical phase with NSI-566. Further clinical development on lysosomal diseases application pending NSI-566 ALS ongoing trial.
Parkinson’s Disease
Preclinical phase with NSI-566. Further clinical development on Parkinson’s disease application pending NSI-566 ALS ongoing trial.
Huntington’s Disease
Preclinical phase with NSI-566. Further clinical development on Huntington’s disease application pending NSI-566 ALS ongoing trial.
Cerebral Palsy
Preclinical phase with NSI-566. Further clinical development on cerebral palsy application pending NSI-566 ALS ongoing trial.
Ischemic Spastic Paraplegia
Preclinical phase with the University of California at San Diego. Lead collaborator, Dr. Martin Marsala, PhD authored a peer-reviewed paper on study results.
- See more at: http://www.neuralstem.com/patient-info-treatments-in-development#sthash.nZurcjC5.dpuf
Drug Treatments in Development
Major Depressive Disorder
Phase I trial for neurogenic small molecule drug, NSI-189, completed in 4Q13, with data showing statistical significance; and clinically meaningful improvement across all depressive and cognitive measures. Multi-center Phase II commencement expected in 2015. More
Cognitive Deficit in Schizophrenia
Commencement of NSI-189 Phase Ib study in second indication, cognitive deficit in schizophrenia, expected in 2015.
Alzheimer’s Disease
Preclinical phase with NSI-189, which was originally developed to address cognitive indications. Further clinical development on Alzheimer’s disease application pending NSI-189 major depressive disorder ongoing trial.
Cognitive complication due to Diabetes
Preclinical phase with NSI-189. Further clinical development on cognitive complication due to diabetes application pending NSI-189 major depressive disorder ongoing trial.
Stroke
Preclinical phase with NSI-189. Further clinical development on stroke application pending NSI-189 major depressive disorder ongoing trial.
Traumatic Brain Injury
Preclinical phase with NSI-189. Further clinical development on traumatic brain injury application pending NSI-189 major depressive disorder ongoing trial.
Post-Traumatic Stress Disorder
Preclinical phase with NSI-189. Further clinical development on PTSD application pending NSI-189 major depressive disorder ongoing trial.
Neurodegeneration
Preclinical phase with NSI-189. Further clinical development on neurodegeneration application pending NSI-189 major depressive disorder ongoing trial.
Anti-Aging (Nootropic)
Preclinical phase with NSI-189. Further clinical development on anti-aging (nootropic) application pending NSI-189 major depressive disorder ongoing trial.
News Disclaimer:
Press Releases have not been investigated by StockGoodies LLC, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. StockGoodies LLC will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
PR Newswire(Thu, July 23
US District Court Rules In Favor Of Neuralstem In Patent Infringement Case
http://finance.yahoo.com/news/us-district-court-rules-favor-114500810.html
PR Newswire(Mon, Jun 29)
Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market
http://finance.yahoo.com/news/neuralstem-inc-announces-approval-listing-132200696.html
PR Newswire(Fri, Jun 26)
Preclinical Data On Neuralstem's Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer's Disease Presented At International Society For Stem Cell Research Annual Meeting
http://finance.yahoo.com/news/preclinical-data-neuralstems-genetically-modified-113200128.html
Contact
Neuralstem, Inc.
20271 Goldenrod Lane
Germantown, MD 20876
United States - Map
Phone: 301-366-4841
Website: http://www.neuralstem.com
Goodies Newsletter Sign Up http://www.stockgoodies.com
WANT A QUICKER WAY TO GET OUR ALERTS?
TEXT "Stock" to 31279
Contact Us admin@stockgoodies.com
